How can earnouts, CVRs, and stock consideration bridge a valuation gap between buyer and seller?

When the bid-ask gap is about disagreement over future value or risk, structure can share that risk rather than forcing a single price.

• Earnout — part of the price is paid later, contingent on the target hitting agreed milestones (revenue, EBITDA, a product approval); the seller gets upside if optimistic projections prove out, the buyer avoids overpaying if they don't. Common in private/founder deals.
• CVR (contingent value right) — a tradable/contractual right paying out on a specific event (often a drug approval or litigation outcome in biotech/pharma); bridges disagreement over a binary catalyst.
• Stock consideration — paying in shares lets the seller share in synergy upside and in the combined entity's performance, and softens the buyer's cash/financing strain, but transfers market risk to the seller until close. Each tool aligns incentives and lets a deal clear when a single fixed cash price can't.